Method for iterative o-c and c-c bond formation
Patent Information
- Application Number
- PCT/US2025/060917
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-23
- Filing Date
- 2025-12-22
- Publication Date
- 2026-11-19
AI Technical Summary
The challenge lies in developing oxygen iteration handles for iterative module linking in medicines, materials, and functional molecules, as existing methods result in uncontrolled oligomerization and lack compatibility with automated purification procedures.
The method involves combining specific compounds of formulas (II) and (III) to form compounds of Formula I, utilizing boron with sp3 hybridization and various functional groups, along with palladium catalysts and bases, to facilitate controlled C-O and C-C bond formation.
Enables controlled iterative linking of modules through C-O bonds, allowing for generalized purification and automation compatibility.
Smart Images

Figure US2025060917_19112026_PF_FP_ABST
Abstract
Description
[0001] UIX-05225
[0002] METHOD FOR ITERATIVE 0-C AND C-C BOND FORMATION RELATED APPLICATIONS
[0003] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 737,908, filed December 23, 2024.
[0004] STATEMENT OF GOVERNMENT SUPPORT
[0005] This invention was made with government support under 2019897 awarded by the National Science Foundation. The government has certain rights in the invention.
[0006] BACKGROUND
[0007] N-Methyliminodiacetic acid (MID A) and tetramethyl N- methyliminodiacetic acid (TIDA) boronates are used as carbon-based iteration-enabling groups that reversibly attenuate the reactivity of carbon atoms and enable generalized purification via catch and release chromatography. This capability enables modules to be linked iteratively via C-C bonds. Module-linking O-C also appear in many types of medicines, materials, and other functional molecules, but the ability to connect iteratively modules with an oxygen atom as the iteration handle, rather than a carbon atom, remains an unresolved challenge. For example, the required bifunctional halo-hydroxyl building blocks would undergo uncontrolled oligomerization under cross -coupling conditions, and known O-protecting groups did not enable generalized purification procedures compatible with automation. In view of the foregoing, there is an unmet need to develop oxygen iteration handles.
[0008] SUMMARY OF THE INVENTION
[0009] In certain aspects, the present disclosure provides methods of making a compound of formula (I):
[0010]
[0011] (i);
[0012] comprising combining a compound of formula (II):UIX-05225
[0013]
[0014] and a compound of formula (III):
[0015] >
[0016]
[0017] (HI);
[0018] thereby forming the compound of Formula I;
[0019] wherein:
[0020] A is aryl or heteroaryl;
[0021] E is aryl or heteroaryl;
[0022] B is a boron having sp3hybridization;
[0023] n is an integer selected from 0, 1, 2, 3, or 4;
[0024] m is an integer selected from 0, 1, 2, 3, or 4;
[0025] X1is a halogen;
[0026] X2is a halogen;
[0027] Z1is -OH or -SH;
[0028] Z2is -O- or -S-;
[0029] R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;
[0030] R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0031] R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0032] R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0033] R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0034] R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl; andUIX-05225
[0035] R26is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
[0036] In further aspects, the present disclosure provides compounds of Formula (III):
[0037]
[0038] (HI);
[0039] or a salt thereof;
[0040] wherein:
[0041] A is aryl or heteroaryl;
[0042] B is a boron having sp3hybridization;
[0043] n is an integer selected from 0, 1, 2, 3, or 4;
[0044] X1is a halogen;
[0045] R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;
[0046] R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;
[0047] R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;
[0048] R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;
[0049] R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl; and
[0050] R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
[0051] In yet further aspects, the present disclosure provides methods of making a compound of Formula (III):
[0052]
[0053] wherein the methods comprise combining a compound of Formula (XII):UIX-05225
[0054]
[0055] (XII);
[0056] and a compound of Formula (XIII):
[0057]
[0058] (XIII);
[0059] thereby forming the compound of Formula (III);
[0060] wherein:
[0061] A is aryl or heteroaryl;
[0062] B is a boron having sp3hybridization;
[0063] n is an integer selected from 0, 1, 2, 3, or 4;
[0064] X1is a halogen;
[0065] R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;
[0066] R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0067] R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0068] R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0069] R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; and
[0070] R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
[0071] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A is a schematic showing a representative TIDA boronate compared to the CbzTIDA and BnTIDA reagents.UIX-05225
[0072] FIG. IB is a schematic showing BnTIDA undergoing a representative cross-coupling reaction, in addition to depicting that BnTIDA enables catch-and-release purification of cross -coupling products.
[0073] FIG. 2 is a schematic showing a generalized reaction scheme for iterative C-0 bond formation.
[0074] DETAILED DESCRIPTION OF THE INVENTION
[0075] Methods ofC-O / C-C Bond Formation
[0076] In certain aspects, the present disclosure provides methods of making a compound of formula (I):
[0077]
[0078] (i);
[0079] comprising combining a compound of formula (II):
[0080]
[0081] and a compound of formula (III):
[0082]
[0083] (HI);
[0084] thereby forming the compound of Formula I;
[0085] wherein:
[0086] A is aryl or heteroaryl;
[0087] E is aryl or heteroaryl;
[0088] B is a boron having sp3hybridization;UIX-05225
[0089] n is an integer selected from 0, 1, 2, 3, or 4;
[0090] m is an integer selected from 0, 1, 2, 3, or 4;
[0091] X1is a halogen;
[0092] X2is a halogen;
[0093] Z1is -OH or -SH;
[0094] Z2is -O- or -S-;
[0095] R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and
[0096] R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0097] R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0098] R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0099] R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0100] R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl; and R26is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
[0101] In certain embodiments, the methods further comprise a base selected from the group consisting of potassium trimethylsilanolate, triethylamine, pyridine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 2,2,6,6-tetramethylpiperidine, NaHCCh, K2CO3, CS2CO3, and K3PO4. In further embodiments, A is phenyl. In yet further embodiments, each of R20, R21, R22, R23, and R24is methyl. In still further embodiments, R25is H.
[0102] In certain embodiments, X1is chloro or bromo. In further embodiments, X1is chloro. In yet further embodiments, X2is bromo or iodo.
[0103] In still further embodiments, the methods comprise combining the compound of Formula (I), a compound of Formula (V):
[0104]
[0105] a palladium catalyst, and a base;UIX-05225
[0106] thereby forming a compound of Formula (IV):
[0107]
[0108] wherein:
[0109] G is aryl or heteroaryl;
[0110] p is an integer selected from 0, 1, 2, 3, and 4;
[0111] R27is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, hydroxyl, halogen, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl;
[0112] Y1is selected from the group consisting of -OH, -SH, -B(pin), -B(neop), -B(dan), -B(MIDA), and -B(OH)2; and
[0113] Y2is -O-, -S-, or a bond.
[0114] In certain embodiments, Y1is -OH. In further embodiments, Y1is -SH. In yet further embodiments, Y1is -B(OH)2. In still further embodiments, Y2is -O-. In certain embodiments, Y2is -S-. In further embodiments, Y2is a bond. In yet further embodiments, the palladium catalyst is selected from the group consisting of (t-Bu-XPhos)Pd G3, (t-Bu-XPhos)Pd G4, (XPhos)Pd G3, (XPhos)Pd G4, Pd(PPh3)4, (RuPhos)Pd G3, (RuPhos)Pd G4, (XantPhos)Pd G3, (XantPhos)Pd G4, (t-Bu-P)3Pd G3, (t-Bu-P)3Pd G4, (SPhos)Pd G3, (Sphos)Pd G4, Pd(OAc)2, (Pd)2(DBA)3, and Pd(PPh3)2(Cl)2. In still further embodiments, the palladium catalyst is (t-Bu-XPhos)Pd G3 or (t-Bu-P)3Pd G4.
[0115] In certain embodiments, the base is selected from the group consisting of potassium trimethylsilanolate, triethylamine, pyridine, 2,6-lutidine, l,8-diazabicyclo[5.4.0]undec-7-ene, 2,2,6,6-tetramethylpiperidine, NaHCO3, K2CO3, Cs2CO3, and K3PO4. In further embodiments, the base is potassium trimethylsilanolate.
[0116] In yet further embodiments, the methods further comprise combining the compound of Formula (IV) and a reducing agent, thereby forming a compound of Formula (VI):
[0117]
[0118] UIX-05225
[0119] In still further embodiments, the reducing agent is selected from the group consisting of sodium tetraacetoxyborohydride, diisobutylaluminum hydride, lithium aluminum hydride, lithium borohydride, Pd / C and H2, Pd / C and NaBFU, Pd / C, H2, and NaBFU, or a combination of any of them. In certain embodiments, the reducing agent is the combination of Pd / C and NaBH4.
[0120] In further embodiments, the methods further comprise combining the compound of Formula (VI), a compound of Formula (VIII):
[0121]
[0122] (VIII);
[0123] a palladium catalyst, and a base;
[0124] thereby forming a compound of Formula (VII):
[0125]
[0126] (VII);
[0127] wherein:
[0128] J is aryl or heteroaryl;
[0129] q is an integer selected from 0, 1, 2, 3, or 4;
[0130] R28is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, hydroxyl, halogen, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl;
[0131] Y3is halogen; and Y4is -O- or -S-; and
[0132] the palladium catalyst is selected from the group consisting of Pd(OAc)2, (SPhos)Pd(OAc)2, (SPhos)Pd G3, (t-Bu-P)3Pd G3, (t-Bu-P)3Pd G4, and (SPhos)Pd G4.
[0133] In yet further embodiments, the palladium catalyst is (t-Bu-P)3Pd G3. In still further embodiments, the base is potassium trimethylsilanolate.UIX-05225
[0134] In certain embodiments, the method further comprises combining the compound of Formula (VIII) and a reducing agent, thereby forming a compound of Formula (IX):
[0135]
[0136] (IX).
[0137] In further embodiments, the reducing agent is a combination of NaBFU and Pd / C. In yet further embodiments, the palladium catalyst is a so-called “Buchwald precatalyst.” Buchwald precatalysts are transition metal complexes used in, for example, cross-coupling reactions, and are of the general form (L(M) G1-G4), wherein L is a ligand, M is a transition metal, such as palladium, and G indicates the generational series, for example, (XPhos)Pd G3. A list of transition metal catalysts, including Buchwald precatalysts, used in this disclosure and their standard nomenclature follows below. In still further embodiments, the palladium catalyst is selected from the group consisting of (t-Bu-XPhos)Pd G3 [(2-dicyclohexylphosphino-2',4',6'-triisopropyl- 1 , 1 '-biphenyl)[2-(2'-amino- 1 , 1 '-biphenyl)] palladium(II) methanesulfonate], (t-Bu-XPhos)Pd G4 [(SP-4-3)-[2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl[l,r-biphenyl]-2-yl]phosphine](methanesulfonato-KO)[2'-(methylamino-KN)[l,l'-biphenyl]-2-yl-KC]palladium], (XPhos)Pd G3 [(2-dicyclohexylphosphino-2',4',6'-triisopropyl- 1 , 1 '-biphenyl)[2-(2'-amino- 1 , 1 '-biphenyl)] palladium(II) methanesulfonate], (XPhos)Pd G4 [(SP-4-3)-[dicyclohexyl[2',4',6'-tris(l-methylethyl)[l,l'-biphenyl]-2-yl]phosphine] (methanesulfonato-KO)[2'-(methylamino-KN)[ 1 , 1 '-biphenyl] -2-yl-KC]palladium], Pd(PPhs)4 [tetrakis(triphenylphosphine)palladium(0)], (RuPhos)Pd G3 [(2-dicyclohexylphosphino-2',6'-diisopropoxy- 1 , 1 '-biphenyl)[2-(2'-amino- 1, 1 biphenyl)]palladium(II) methanesulfonate], (RuPhos)Pd G4 [[dicyclohexyl(2',6'-diisopropoxy-2-biphenylyl)phosphine-KP](methanesulfonatato-KO)[2'-(methylamino-KN)-2-biphenylyl-KC2] palladium], (XantPhos)Pd G3 [[(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2'-amino-l,r-biphenyl)]palladium(II) methane sulfonate], (XantPhos)Pd G4 [(SP-4-3)-[[5-(diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-yl] diphenylphosphine-KP] (methanesulfonato-KO) [2 '- (methylamino-KN) [1,1 '-biphenyl] -2-yl-KC]- palladium], (t-Bu-P)sPd G3 [(tris(2-methyl-2-propanyl)phosphino-2',6'-diisopropoxy-l,r-biphenyl)[2-(2'-amino-l,r-biphenyl)]palladium(II) methanesulfonate], (t-Bu-P)sPd G4 [(methanesulfonatato-KO)[2'-(methylamino-KN)-2-biphenylyl-KC2] [tris(2-methyl-2-propanyl)phosphine]palladium], (Sphos)Pd G3 [(2-dicyclohexylphosphino-2',6'-UIX-05225
[0138] dimethoxybiphenyl) [2-(2'-amino-l '-biphenyl)]palladium(II) methane sulfonate], (Sphos)Pd G4 [(methanesulfonato-KO)[2'-(methylamino)-2-biphenylyl]palladium - dicyclohexyl(2',6'-dimethoxy-2-biphenylyl)phosphine], Pd(OAc)2 [palladium(II) acetate], (Pd)2(DBA)s [tris(dibenzylideneacetone)dipalladium(0)], and Pd(PPhs)2(Cl)2 [bis(triphenylphosphine)palladium(II) dichloride] .
[0139] Compounds of the Disclosure, and Methods of Making Thereof
[0140] In further aspects, the present disclosure provides compounds of Formula (III):
[0141]
[0142] (HI);
[0143] or a salt thereof;
[0144] wherein:
[0145] A is aryl or heteroaryl;
[0146] B is a boron having sp3hybridization;
[0147] n is an integer selected from 0, 1, 2, 3, or 4;
[0148] X1is a halogen;
[0149] R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;
[0150] R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;
[0151] R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;
[0152] R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;
[0153] R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl; and
[0154] R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
[0155] In certain embodiments, A is phenyl. In further embodiments, R25is H. In yet further embodiments, each of R20, R21, R22, R23, and R24is methyl. In still further embodiments, X1isUIX-05225
[0156] chloro or bromo. In certain embodiments, X1is chloro. In further embodiments, the compound is:
[0157]
[0158] In yet further aspects, the present disclosure provides methods of making a compound of Formula (III):
[0159]
[0160] (HI);
[0161] wherein the methods comprise combining a compound of Formula (XII):
[0162]
[0163] (XII);
[0164] and a compound of Formula (XIII):
[0165]
[0166] (XIII);
[0167] thereby forming the compound of Formula (III);
[0168] wherein:
[0169] A is aryl or heteroaryl;
[0170] B is a boron having sp3hybridization;
[0171] n is an integer selected from 0, 1, 2, 3, or 4;
[0172] X1is a halogen;
[0173] R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and
[0174] R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;UIX-05225
[0175] R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0176] R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
[0177] R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; and
[0178] R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
[0179] In certain embodiments, A is phenyl. In further embodiments, R25is H. In yet further embodiments, X1is chloro or bromo. In still further embodiments, each of R20, R21, R22, R23, and R24is methyl. In certain embodiments, the compound of Formula (XII) is:
[0180]
[0181] salt thereof.
[0182] In further embodiments, the compound of Formula (XIII) is:
[0183]
[0184] salt thereof.
[0185] Definitions
[0186] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0187] The term “heteroatom” is art-recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium, and alternatively oxygen, nitrogen or sulfur.
[0188] The term “alkyl” as used herein is a term of art and refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight-chain or branched-chain alkyl has about 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), and alternatively, about 20 or fewer, or 10 or fewer. In certain embodiments, the term “alkyl” refers to a C1-C10 alkyl group. In certain embodiments, the term “alkyl” refers to a Ci-Ce alkyl group, for example a Ci-Ce straight-chain alkyl group. In certain embodiments, the term “alkyl” refers to a C3-C12 branched-chain alkyl group. In certain embodiments, the term “alkyl” refers to a C3-Cs branched-chain alkyl group. Representative examples of alkyl include, but are not limitedUIX-05225
[0189] to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
[0190] The term “cycloalkyl” means mono- or bicyclic or bridged saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Certain cycloalkyls have from 5-12 carbon atoms in their ring structure, and may have 6-10 carbons in the ring structure. Preferably, cycloalkyl is (C3-C7)cycloalkyl, which represents a monocyclic saturated carbocyclic ring, having from 3 to 7 carbon atoms. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems include bridged monocyclic rings and fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (z.e., a bridging group of the form -(CH2)W-, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionally substituted. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted.
[0191] The term “(cycloalkyl)alkyl” as used herein refers to an alkyl group substituted with one or more cycloalkyl groups. An example of cycloalkylalkyl is cyclohexylmethyl group.
[0192] The term “heterocycloalkyl” as used herein refers to a radical of a non-aromatic ring system, including, but not limited to, monocyclic, bicyclic, and tricyclic rings, which can be completely saturated or which can contain one or more units of unsaturation, for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system, and having 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of exemplification, which should not be construed as limiting the scope of this invention, the following are examples of heterocyclic rings: aziridinyl, azirinyl, oxiranyl, thiiranyl, thiirenyl, dioxiranyl, diazirinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, azetyl, oxetanyl,UIX-05225
[0193] oxetyl, thietanyl, thietyl, diazetidinyl, dioxetanyl, dioxetenyl, dithietanyl, dithietyl, dioxalanyl, oxazolyl, thiazolyl, triazinyl, isothiazolyl, isoxazolyl, azepines, azetidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxopiperidinyl, oxopyrrolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, quinuclidinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, trithianyl, and 2-azobicyclo [3.1.0] hexane. A heterocycloalkyl group is optionally substituted by one or more substituents as described below.
[0194] The term “(heterocycloalkyl)alkyl” as used herein refers to an alkyl group substituted with one or more heterocycloalkyl (i.e., heterocyclyl) groups.
[0195] The term “alkenyl” as used herein means a straight or branched chain hydrocarbon radical containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l -heptenyl, and 3-decenyl. The unsaturated bond(s) of the alkenyl group can be located anywhere in the moiety and can have either the (Z) or the (E) configuration about the double bond(s).
[0196] The term “alkynyl” as used herein means a straight or branched chain hydrocarbon radical containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
[0197] The term “alkylene” is art-recognized, and as used herein pertains to a diradical obtained by removing two hydrogen atoms of an alkyl group, as defined above. In one embodiment an alkylene refers to a disubstituted alkane, i.e., an alkane substituted at two positions with substituents such as halogen, azide, alkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. That is, in one embodiment, a “substituted alkyl” is an “alkylene”.
[0198] The term “amino” is a term of art and as used herein refers to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:UIX-05225
[0199]
[0200] wherein Ra, Rb, and Rceach independently represent a hydrogen, an alkyl, an alkenyl, -(CH2)X-Rd, or Raand Rb, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; Rd represents an aryl, a heteroaryl, a cycloalkyl, a cycloalkenyl, a heterocyclyl or a polycyclyl; and x is zero or an integer in the range of 1 to 8. In certain embodiments, only one of Raor Rb may be a carbonyl, e.g., Ra, Rb, and the nitrogen together do not form an imide. In other embodiments, Raand Rb (and optionally Rc) each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH2)X-Rd. In certain embodiments, Raand Rb are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, arylalkyl, heteroarylalkyl, alkoxyalkyl, or haloalkyl, any of which may be further substituted (e.g., by halogen, alkyl, alkoxy, hydroxy, and so forth). In certain embodiments, the term “amino” refers to -NH2.
[0201] In certain embodiments, the term “alkylamino” refers to -NH(alkyl).
[0202] In certain embodiments, the term “dialkylamino” refers to -N(alkyl)2.
[0203] The term “amido”, as used herein, means -NHC(=O)-, wherein the amido group is bound to the parent molecular moiety through the nitrogen. Examples of amido include alkylamido such as CHsC(=O)N(H)- and CHsCH2C(=O)N(H)-.
[0204] The term “acyl” is a term of art and as used herein refers to any group or radical of the form RCO- where R is any organic group, e.g., alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl. Representative acyl groups include acetyl, benzoyl, and malonyl.
[0205] The term “aminoalkyl” as used herein refers to an alkyl group substituted with one or more one amino groups. In one embodiment, the term “aminoalkyl” refers to an aminomethyl group, i.e., -CH2NH2.
[0206] The term “aminoacyl” is a term of art and as used herein refers to an acyl group substituted with one or more amino groups.
[0207] The term “aminothionyl” as used herein refers to an analog of an aminoacyl in which the O of RC(O)- has been replaced by sulfur, hence is of the form RC(S)-.
[0208] The term “phosphoryl” is a term of art and as used herein may in general be represented by the formula:UIX-05225
[0209]
[0210] wherein Q50 represents S or O, and R59 represents hydrogen, a lower alkyl or an aryl; for example, -P(O)(Ome)- or -P(O)(OH)2. When used to substitute, e.g., an alkyl, the phosphoryl group of the phosphorylalkyl may be represented by the general formulas:
[0211] Q50 Q50
[0212] - Q51 - - o - - Q51— p-OR59
[0213] OR I59 OR I59
[0214] wherein Q50 and R59, each independently, are defined above, and Q51 represents O, S or N; for example, -O-P(O)(OH)Ome or -NH-P(0)(0H)2. When Q50 is S, the phosphoryl moiety is a “phosphorothioate.”
[0215] The term “aminophosphoryl” as used herein refers to a phosphoryl group substituted with at least one amino group, as defined herein; for example, -P(0)(0H)Nme2.
[0216] The term “azide” or “azido”, as used herein, means an -N3 group.
[0217] The term “carbonyl” as used herein refers to -C(=O)-.
[0218] The term “thiocarbonyl” as used herein refers to -C(=S)-.
[0219] The term “alkylphosphoryl” as used herein refers to a phosphoryl group substituted with at least one alkyl group, as defined herein; for example, -P(O)(OH)Me.
[0220] The term “alkylthio” as used herein refers to alkyl-S-. The term “(alkylthio)alkyl” refers to an alkyl group substituted by an alkylthio group.
[0221] The term “carboxy”, as used herein, means a -CO2H group.
[0222] The term “aryl” is a term of art and as used herein refers to includes monocyclic, bicyclic and polycyclic aromatic hydrocarbon groups, for example, benzene, naphthalene, anthracene, and pyrene. Typically, an aryl group contains from 6-10 carbon ring atoms (i.e., (Ce-Cio)aryl). The aromatic ring may be substituted at one or more ring positions with one or more substituents, such as halogen, azide, alkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is an aromatic hydrocarbon, e.g., the other cyclic rings may beUIX-05225
[0223] cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. In certain embodiments, the term “aryl” refers to a phenyl group.
[0224] The term “heteroaryl” is a term of art and as used herein refers to a monocyclic, bicyclic, and polycyclic aromatic group having 3 to 12 total atoms including one or more heteroatoms such as nitrogen, oxygen, or sulfur in the ring structure. Exemplary heteroaryl groups include azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indolinyl, indazolyl, isoindolinyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo [3, 4-d] pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thienyl, thiomorpholinyl, triazolyl or tropanyl, and the like. The “heteroaryl” may be substituted at one or more ring positions with one or more substituents such as halogen, azide, alkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. The term “heteroaryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is an aromatic group having one or more heteroatoms in the ring structure, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls.
[0225] The term “aralkyl” or “arylalkyl” is a term of art and as used herein refers to an alkyl group substituted with an aryl group, wherein the moiety is appended to the parent molecule through the alkyl group.
[0226] The term “heteroaralkyl” or “heteroarylalkyl” is a term of art and as used herein refers to an alkyl group substituted with a heteroaryl group, appended to the parent molecular moiety through the alkyl group.
[0227] The term “alkoxy” as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
[0228] The term “alkoxyalkyl” refers to an alkyl group substituted by an alkoxy group.
[0229] The term “alkoxycarbonyl” means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(=O)-, as defined herein.UIX-05225
[0230] Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and / c / V-butoxycarbonyl.
[0231] The term “alkylcarbonyl”, as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1 -oxopropyl, 2, 2-dimethyl-l -oxopropyl, 1 -oxobutyl, and 1 -oxopentyl.
[0232] The term “arylcarbonyl”, as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of arylcarbonyl include, but are not limited to, benzoyl and (2-pyridinyl)carbonyl.
[0233] The term “alkylcarbonyloxy” and “arylcarbonyloxy”, as used herein, means an alkylcarbonyl or arylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and / -butylcarbonyloxy. Representative examples of arylcarbonyloxy include, but are not limited to phenylcarbonyloxy.
[0234] The term “alkenoxy” or “alkenoxyl” means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkenoxyl include, but are not limited to, 2-propen-l-oxyl (i.e., CH2=CH-CH2-O-) and vinyloxy (i.e., CH2=CH-0-).
[0235] The term “aryloxy” as used herein means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
[0236] The term “heteroaryloxy” as used herein means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
[0237] The term “carbocyclyl” as used herein means a monocyclic or multicyclic (e.g., bicyclic, tricyclic, etc.) hydrocarbon radical containing from 3 to 12 carbon atoms that is completely saturated or has one or more unsaturated bonds, and for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system (e.g., phenyl). Examples of carbocyclyl groups include 1 -cyclopropyl, 1-cyclobutyl, 2-cyclopentyl, 1 -cyclopentenyl, 3-cyclohexyl, 1 -cyclohexenyl and 2-cyclopentenylmethyl.
[0238] The term “cyano” is a term of art and as used herein refers to -CN.
[0239] The term “halo” is a term of art and as used herein refers to -F, -Cl, -Br, or -I.
[0240] The term “haloalkyl” as used herein refers to an alkyl group, as defined herein, wherein some or all of the hydrogens are replaced with halogen atoms.
[0241] The term “hydroxy” is a term of art and as used herein refers to -OH.UIX-05225
[0242] The term “hydroxyalkyl”, as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.
[0243] The term “silyl”, as used herein, includes hydrocarbyl derivatives of the silyl (HsSi-) group (i.e., (hydrocarbyl Si-), wherein a hydrocarbyl groups are univalent groups formed by removing a hydrogen atom from a hydrocarbon, e.g., ethyl, phenyl. The hydrocarbyl groups can be combinations of differing groups which can be varied in order to provide a number of silyl groups, such as trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tertbutyldimethylsilyl (TBS / TBDMS), triisopropylsilyl (TIPS), and [2-(trimethylsilyl)ethoxy] methyl (SEM) .
[0244] The term “silyloxy”, as used herein, means a silyl group, as defined herein, is appended to the parent molecule through an oxygen atom.
[0245] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, compounds of the present invention may also be optically active. The present invention contemplates all such compounds, including cis- and / / v -isomers, (R)- and (S)-enantiomers, diastereoisomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
[0246] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
[0247] It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, fragmentation, decomposition, cyclization, elimination, or other reaction.UIX-05225
[0248] The term “substituted” is also contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents may be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
[0249] In certain embodiments, the optional substituents contemplated in this invention include halogen, azide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclyl, (heterocyclyl)alkyl, hydroxyl, alkoxyl, amino, aminoalkyl, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether (e.g., -alkylene-O(alkyl)), alkylthio, sulfonyl, sulfonamide, ketone (e.g., -CO(alkyl)), aldehyde (-C(O)H), ester (e.g., -COO(alkyl)), haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, and cyano.
[0250] As used herein, the term “optionally substituted” or “substituted or unsubstituted” when it precedes a list of chemical moieties means that the list of chemical moieities that follow are each substituted or unsubstituted. For example, “substituted or unsubstituted aryl, heteroaryl, and cycloalkyl” or “optionally substituted aryl, heteroaryl, and cycloalkyl” means substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted cycloalkyl.
[0251] The phrase “protecting group”, as used herein, means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 2nded.; Wiley: New York, 1991). Protected forms of the inventive compounds are included within the scope of this invention.
[0252] For purposes of the invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67thEd., 1986-87, inside cover.
[0253] Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (ed. Parker, S., 1985),UIX-05225
[0254] McGraw-Hill, San Francisco, incorporated herein by reference). Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0255] The term “pharmaceutically acceptable salt” as used herein includes salts derived from inorganic or organic acids including, for example, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, phosphoric, formic, acetic, lactic, maleic, fumaric, succinic, tartaric, glycolic, salicylic, citric, methanesulfonic, benzenesulfonic, benzoic, malonic, trifluoroacetic, trichloroacetic, naphthalene-2-sulfonic, and other acids. Pharmaceutically acceptable salt forms can include forms wherein the ratio of molecules comprising the salt is not 1:1. For example, the salt may comprise more than one inorganic or organic acid molecule per molecule of base, such as two hydrochloric acid molecules per molecule of compound of Formula I. As another example, the salt may comprise less than one inorganic or organic acid molecule per molecule of base, such as two molecules of compound of Formula I per molecule of tartaric acid.
[0256] The terms “carrier” and “pharmaceutically acceptable carrier” as used herein refer to a diluent, adjuvant, excipient, or vehicle with which a compound is administered or formulated for administration. Non-limiting examples of such pharmaceutically acceptable carriers include liquids, such as water, saline, and oils; and solids, such as gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating, flavoring, and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in Remington’s Pharmaceutical Sciences by E.W. Martin, herein incorporated by reference in its entirety.
[0257] As used herein, the term “oxidizing agent” refers to a reagent that accepts one or more electrons from a substrate. Certain oxidizing agents may also induce the formation of new bonds to oxygen. Illustrative examples of oxidizing agent include, but are not limited to, oxygen, ozone, hydrogen peroxide, periodic acid, sodium periodate, Dess-Martin periodinane, peracetic acid, meto-chloroperbenzoic acid, fluorine, chlorine, bromine, iodine, nitric acid, potassium nitrate, potassium chlorate, peroxydisulfuric acid, peroxymonosulfuric acid, sodium hypochlorite, interhalogen compounds (such as IC1), chromic acids, chromium trioxide, pyridinium chlorochromate, sodium dichromate, potassium permanganate, manganese heptoxide, sodium perborate, nitrous oxide, nitrogen dioxide, dinitrogen tetroxide, ceric ammonium nitrate, and ceric sulfate.
[0258] As used herein, the term “reducing agent” refers to a reagent that donates one or more electrons to a substrate. Illustrative examples of reducing agents include, but are not limited to,UIX-05225
[0259] lithium, sodium, potassium, magnesium, aluminum, iron, tin, copper, zinc, sodium hydride, lithium aluminum hydride, sodium borohydride, lithium borohydride, sodium tetraacetoxyborohydride, NaAlH2(OCH2CH2OCHs)2, Na(Hg), Zn(Hg), diborane, nickel boride, sodium dithionate, diisobutylaluminum hydride, and ascorbic acid.
[0260] As used herein, the term “B(pin)” is art recognized and refers to a pinacol boronate moiety. The pinacol boronate moiety has the following structure:
[0261]
[0262] wherein the wavy bond represents the point of attachment to the parent molecular moiety.
[0263] As used herein, the term “B(dan)” is art recognized and refers to a 2,3-dihydro-lH-naphtho[l,8-de][l,3,2]diazaborinine moiety. The 2,3-dihydro-lH-naphtho[l,8-de][l,3,2]diazaborinine moiety has the following structure:
[0264]
[0265] wherein the wavy bond represents the point of attachment to the parent molecular moiety.
[0266] As used herein, the term “B(neop)” is art recognized and refers to a neopentyl glycol boronate moiety. The neopentyl glycol boronate moiety has the following structure:
[0267]
[0268] wherein the wavy bond represents the point of attachment to the parent molecular moiety.
[0269] As used herein, the term “B(MIDA)” is art recognized and refers to an N-methyliminodiacetic acid boronate moiety. The A-methyliminodiacetic acid boronate moiety has the following structure:
[0270]
[0271] wherein the wavy bond represents the point of attachment to the parent molecular moiety.
[0272] As used herein, the term “B(TIDA)” is art recognized and refers to a tetramethyl-A-methyliminodiacetic acid boronate moiety. The tetramethyl-A-methyliminodiacetic acid boronate moiety has the following structure:UIX-05225
[0273]
[0274] wherein the wavy line represents the point of attachment to the remainder of the molecule.
[0275] EXAMPLES
[0276] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
[0277] Example 1: Exemplary Synthesis of Compounds of the Disclosure
[0278] Exemplary synthesis ofBnTIDA
[0279] 8-(4-(chloromethyl)phenyl)-3,3,4,5,5-pentamethyldihydro-4k^,8k^- 11.3.2 |oxazaborolo| 2.3-61| 1.3.2 |oxazaborole-2.6(3 / / .5 / / )-dione (3)
[0280]
[0281] To a 1 L round bottom flask with a stir bar was added the TIDA ligand 1 (20.3 g, 100 mmol, 1.0 equiv.), 4- (chloromethyl) phenylboronic acid 2 (17.0 g, 100 mmol, 1 equiv.) and were dissolved in benzene (300 mL) and DMSO (100 mL). The solution was stirred and then the flask was fitted with a Dean- Stark trap and heated to reflux. After refluxing for 6 h, the reaction mixture was cooled to room temperature and then concentrated by rotary evaporation. The resultant DMSO solution was diluted with EtOAc (250 mL) and transferred to a separatory funnel, rinsing the vessel with additional EtOAc. The organic solution was washed with brine (200 mL x 3 to 6 times to ensure complete removal of DMSO), dried over MgSO4, filtered through a cotton plug, and then concentrated by rotary evaporation. The crude concentrate was dissolved in minimal hot acetone with gentle heating and added dropwise by pipette to a vigorously stirred Erlenmeyer flask containing hexanes:Et2O (1:1, 1 L) causing precipitation of the product. Stirring continued until no further precipitation was observed. The product was collected by vacuum filtration through a fine fritted funnel and washed with Et2O (250 mL x 3) to afford a white solid (30.3 g, 90 mmol, 90% yield).UIX-05225
[0282] Installation ofBnTIDA on an exemplary phenol
[0283] 8-(4-((3-bromophenoxy)methyl)phenyl)-3 5,5-pentamethyldihydro-414,814.
[0284] [l,3,2]oxazaborolo[2,3-^][l,3,2]oxazaborole-2,6(3 / / ,5 / / )-dione (5)
[0285]
[0286] &
[0287] To an oven dried, septa capped, glass 40 mL vial with a stir bar was added 3 (0.674 g, 2.0 mmol, 1.0 equiv.), 3-bromophenol 4 (0.415 g, 2.4 mmol, 1.2 equiv.), caesium carbonate (0.976 g, 3.0 mmol, 1.5 equiv.), tetra-zi-butylammonium iodide (TBAI, 1.107 g, 3.0 mmol, 1.5 equiv.) and acetone (20 mL). The vial was sealed with a Teflon septum screw cap and the mixture was stirred for 6 h at 60 °C under positive pressure of nitrogen. After the completion of the reaction, the crude mixture was concentrated by rotary evaporation and then EtOAc (20 mL) was added to the vial. The organic solution was washed with H2O (25 mL x 4), removing water with a pipette after each wash. The organic layer was dried over anhydrous MgSO4, filtered through a cotton plug, and then concentrated via rotary evaporation. The crude product mixture was purified by silica gel (10.0 g) column chromatography eluting with 50 to 100% EtOAc / hexanes to yield the title compound 5 as a white solid (0.804 g, 1.7 mmol, 85% yield).
[0288]
[0289] <
[0290] In an argon filled glovebox, an oven dried 7 mL vial equipped with a stir bar was charged with halo-OBnTIDA boronate (1 equiv.), substituted neopentyl ester (1.2 equiv.), potassium trimethylsilanolate (1.5 equiv.) and Pd-P(tBu)3-G3 precatalyst (Sigma Aldrich #804851, CAS NO. 1445086-17-8) (0.10 equiv.). The vial was sealed with a PTFE septum cap, removed from the glovebox and anhydrous THF (1 mL) was added via syringe. If the neopentyl ester was a liquid it was added at this point via syringe through the PTFE septum cap. The vialUIX-05225
[0291] was placed in a pre-equilibrated aluminum heating block at the desired reaction temperature (rt, 50 , or 60 °C) and stirred at 500 rpm for 5 minutes. The vial was removed from the heating block and cooled to room temperature and purified by silica gel column chromatography.
[0292] Scheme 1. Targeted Bneo Substrate Scope
[0293]
[0294] UIX-05225
[0295] Scheme 2. Targeted Phenol & Heteroaryl Halide Scope
[0296]
[0297] Exemplary methods for the removal of the BnTIDA group
[0298] 4'-fluoro-[l,l'-biphenyl]-3-ol (8a)
[0299]
[0300] To a 20 mL vial with a stir bar was added 7a (97.8 mg, 0.2 mmol, 1.0 equiv), NaBH4 (37.8 mg, 5.0 equiv, 1.0 mmol) and 10 wt % of 10% Pd / C (10 mg). The vial was sealed with a septum cap and was then evacuated and backfilled with nitrogen (3x) using a needle attached to a Schlenk line. MeOH (10 mL) was added by syringe and then an empty (deflated) balloon attached to a syringe fitted with a needle was placed through the septum to avoid the buildupUIX-05225
[0301] of pressure while preventing loss of generated hydrogen. The reaction was stirred at room temperature for 2 hours. The reaction mixture was concentrated by rotary evaporation and was then diluted with hexanes (30 mb) and filtered through a silica plug. The hexanes layer was discarded, and the silica plug was flushed with Et2O (100 mL). The Et2O eluent solution was concentrated via rotary evaporation to yield the title compound 8a as a white solid (36 mg, 95 % yield).
[0302] Scheme 3. Targeted BnTIDA Deprotection and C-0 Bond Formation
[0303]
[0304] Scheme 4. Exemplary DDQ-mediated removal of the BnTIDA group
[0305]
[0306] In an argon filled glovebox, an oven dried 20 mL vial equipped with a stir bar was charged with compound 10b (1 equiv.) and DDQ (2,3-Dichloro-5,6-dicyano-l,4-benzoquinone, Sigma Aldrich #D60400, CAS NO. 84-58-2) (2.0 equiv.). The vial was sealed with a PTFE septum cap, removed from the glovebox and anhydrous MeCN (10 mL) was added via syringe. The vial was placed in a pre-equilibrated aluminum heating block at the desired reaction temperature (80 °C) and stirred at 500 rpm for 2 hours. The vial was removed from the heating block and cooled to room temperature and purified by silica gel column chromatography obtain the related desired product 18a.UIX-05225
[0307] Scheme 5. Exemplary removal of the BnTIDA group using NaBH Pd / C
[0308]
[0309] To a 20 mL vial with a stir bar was added 10a (0.2 mmol, 1.0 equiv), NaBfLi (1.0 mmol, 5.0 equiv) and 10 wt % of 10% Pd / C (10 mg). The vial was sealed with a septum cap and was then evacuated and backfilled with nitrogen (3x) using a needle attached to a Schlenk line. MeOH (10 mL) was added by syringe and then an empty (deflated) balloon attached to a syringe fitted with a needle was placed through the septum to avoid the buildup of pressure while preventing loss of generated hydrogen. The reaction was stirred at room temperature for 2 hours. The reaction mixture was concentrated by rotary evaporation and was then diluted with hexanes (30 mL) and filtered through a silica plug. The hexanes layer was discarded, and the silica plug was flushed with Et2O (100 mL). The Et2O eluent solution was concentrated via rotary evaporation to yield the title compound 18a as a white solid (36 mg, 95 % yield).
[0310]
[0311] (BTIDA) (BTIDA) 1 2
[0312] PBn (0.42 mL,4.48 mmol, 1.1 eq.) was added to a suspension of (4-(hydroxymethyl)aryl)boronic acid TIDA ester la (4.08 mmol, 1 eq.) in 4:1 DCM:MeCN (25 mL). After 4 h the reaction mixture was quenched through addition of sat Na2COs (100 mL) followed by water (100 mL). The organic layer was separated, and the aqueous layer washed with DCM (3 x 100 mL). The organics were combined dried over MgSCh, filtered, and concentrated in vacuo. The residue was suspended in acetone (20 mL) followed by addition of 1:1 Et2O:hexanes (300 mL) causing precipitation of the product 2a which was collected by vacuum filtration (yield is in the range between 80-85%).UIX-05225
[0313] Scheme 5. Representative Br-BnTIDA building blocks
[0314]
[0315] Exemplary synthesis of representative bifunctional OBnTIDA building blocks
[0316]
[0317] To an oven dried, septa capped, glass 40 mb vial with a stir bar was added 2a (0.674 g, 2.0 mmol, 1.0 equiv.), 3-bromophenol 3a (0.415 g, 2.4 mmol, 1.2 equiv.), caesium carbonate (0.976 g, 3.0 mmol, 1.5 equiv.), and MeCN (20 mL). The vial was sealed with a Teflon septum screw cap and the mixture was stirred for 6 h at 50 °C under positive pressure of nitrogen. After the completion of the reaction, the crude mixture was concentrated by rotary evaporation and then EtOAc (20 mL) was added to the vial. The organic solution was washed with H2O (25 mL x 4), removing water with a pipette after each wash. The organic layer was dried over anhydrous MgSO4, filtered through a cotton plug, and then concentrated via rotary evaporation. The crude product mixture was purified by silica gel (10.0 g) columnUIX-05225
[0318] chromatography eluting with 50 to 100% EtOAc / hexanes to yield the title compound 4a as a white solid (0.804 g, 1.7 mmol, 85% yield).
[0319] Representative C-0 bond-forming reaction
[0320]
[0321] In an argon filled glovebox, an oven dried 20 mL vial equipped with a stir bar was charged with 18a (1.0 mmol, 1.0 equiv), bromobenzene 24a (1.0 mmol, 1.0 equiv), precatalyst P2 (19-38 mg, 2.0-4.0 mol %), and NaOtBu (115 mg, 1.20 mmol, 1.20 equiv). The vial was sealed with a PTFE septum cap, removed from the glovebox and anhydrous THF (5 mL) was added via syringe. The vial was placed in a pre-equilibrated aluminum heating block at the desired reaction temperature (40 °C) and stirred at 500 rpm for 2 hours. The vial was removed from the heating block and cooled to room temperature and purified by silica gel column chromatography obtain the related desired product 25a.
[0322]
[0323] In an argon filled glovebox, an oven dried 20 mL vial equipped with a stir bar was charged with halo-OBnTIDA boronate 4a (1 equiv.), substituted neopentyl ester 9a (1.2 equiv.), potassium trimethylsilanolate (1.5 equiv.) and Pd-P(tBu)3-G3 precatalyst (Sigma Aldrich #804851, CAS NO. 1445086-17-8) (0.10 equiv.). The vial was sealed with a PTFE septum cap, removed from the glovebox and anhydrous THF (10 mL) was added via syringe.UIX-05225
[0324] If the neopentyl ester was a liquid it was added at this point via syringe through the PTFE septum cap. The vial was placed in a pre-equilibrated aluminum heating block at the desired reaction temperature (rt, 50 V, or 60 °C) and stirred at 500 rpm for 30 minutes. The vial was removed from the heating block and cooled to room temperature and purified by silica gel column chromatography obtain the related desired product 10a.
[0325] INCORPORATION BY REFERENCE
[0326] All US patents and US and PCT patent application publications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
[0327] EQUIVALENTS
[0328] While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
Claims
UIX-05225CLAIMSWe claim:
1. A method of making a compound of formula (I):(i);comprising combining a compound of formula (II):thereby forming the compound of Formula I;wherein:A is aryl or heteroaryl;E is aryl or heteroaryl;B is a boron having sp3hybridization;n is an integer selected from 0, 1, 2, 3, or 4;m is an integer selected from 0, 1, 2, 3, or 4;X1is a halogen;X2is a halogen;Z1is -OH or -SH;Z2is -O- or -S-;UIX-05225R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl; and R26is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
2. The method of claim 1, further comprising a base selected from the group consisting of potassium trimethylsilanolate, triethylamine, pyridine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 2,2,6,6-tetramethylpiperidine, NaHCCh, K2CO3, CS2CO3, and K3PO4.
3. The method of claim 1 or 2, wherein A is phenyl.
4. The method of any one of claims 1-3, wherein each of R20, R21, R22, R23, and R24is methyl.
5. The method of any one of claims 1-4, wherein R25is H.
6. The method of any one of claims 1-5, wherein X1is chloro or bromo.
7. The method of claim 6, wherein X1is chloro.
8. The method of any one of claims 1-7, wherein X2is bromo or iodo.UIX-052259. The method of any one of claims 1-8, further comprising combining the compound of Formula (I), a compound of Formula (V):a palladium catalyst, and a base;thereby forming a compound of Formula (IV):wherein:G is aryl or heteroaryl;p is an integer selected from 0, 1, 2, 3, and 4;R27is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, hydroxyl, halogen, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl;Y1is selected from the group consisting of -OH, -SH, -B(pin), -B(neop), -B(dan), -B(MIDA), and -B(OH)2; andY2is -O-, -S-, or a bond.
10. The method of claim 9, wherein Y1is -OH.
11. The method of claim 9, wherein Y1is -SH.
12. The method of claim 9, wherein Y1is -B(OH)2.
13. The method of claim 9, wherein Y2is -O-.
14. The method of claim 10, wherein Y2is -S-.UIX-0522515. The method of claim 12, wherein Y2is a bond.
16. The method of any one of claims 9-15, wherein the palladium catalyst is selected from the group consisting of (t-Bu-XPhos)Pd G3, (t-Bu-XPhos)Pd G4, (XPhos)Pd G3, (XPhos)Pd G4, Pd(PPh3)4, (RuPhos)Pd G3, (RuPhos)Pd G4, (XantPhos)Pd G3, (XantPhos)Pd G4, (t-Bu-P)3Pd G3, (t-Bu-P)3Pd G4, (SPhos)Pd G3, (Sphos)Pd G4, Pd(OAc)2, (Pd)2(DBA)3, and Pd(PPh3)2(Cl)2.
17. The method of claim 16, wherein the palladium catalyst is (t-Bu-XPhos)Pd G3 or (t-Bu-P)3Pd G4.
18. The method of any one of claims 9-17, wherein the base is selected from the group consisting of potassium trimethylsilanolate, triethylamine, pyridine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 2,2,6,6-tetramethylpiperidine, NaHCO3, K2CO3, Cs2CO3, and K3PO4.
19. The method of claim 18, wherein the base is potassium trimethylsilanolate.
20. The method of any one of claims 9-19, wherein the method further comprises combining the compound of Formula (IV) and a reducing agent, thereby forming a compound of Formula (VI):
21. The method of claim 20, wherein the reducing agent is selected from the group consisting of sodium tetraacetoxyborohydride, diisobutylaluminum hydride, lithium aluminum hydride, lithium borohydride, Pd / C and H2, Pd / C and NaBH4, Pd / C, H2, and NaBH4, or a combination of any of them.
22. The method of claim 21, wherein the reducing agent is the combination of Pd / C and NaBH4.UIX-0522523. The method of any one of claims 20-22, further comprising combining the compound of Formula (VI), a compound of Formula (VIII):(VIII);a palladium catalyst, and a base;thereby forming a compound of Formula (VII):(VII);wherein:J is aryl or heteroaryl;q is an integer selected from 0, 1, 2, 3, or 4;R28is, independently for each occurrence, selected from the group consisting of H, alkyl, cycloalkyl, alkoxy, hydroxyl, halogen, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl;Y3is halogen; and Y4is -O- or -S-; andthe palladium catalyst is selected from the group consisting of Pd(OAc)2, (SPhos)Pd(OAc)2, (SPhos)Pd G3, (t-Bu-P)3Pd G3, (t-Bu-P)3Pd G4, and (SPhos)Pd G4.
24. The method of claim 23, wherein the palladium catalyst is (t-Bu-P)3Pd G3.
25. The method of claim 23 or 24, wherein the base is potassium trimethylsilanolate.UIX-0522526. The method of any one of claims 23-25, wherein the method further comprises combining the compound of Formula (VIII) and a reducing agent, thereby forming a compound of Formula (IX):
27. The method of claim 26, wherein the reducing agent is a combination of NaBFU and Pd / C.
28. A compound of Formula (III):(HI);or a salt thereof;wherein:A is aryl or heteroaryl;B is a boron having sp3hybridization;n is an integer selected from 0, 1, 2, 3, or 4;X1is a halogen;R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl;R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and heteroaryl; andUIX-05225R25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
29. The compound of claim 28, wherein A is phenyl.
30. The compound of claim 28 or 29, wherein R25is H.
31. The compound of any one of claims 28-30, wherein each of R20, R21, R22, R23, and R24is methyl.
32. The compound of any one of claims 28-31, wherein X1is chloro or bromo.
33. The compound of claim 32, wherein X1is chloro.
34. The compound of claim 28, wherein the compound is:
35. A method of making a compound of Formula (III):wherein the method comprises combining a compound of Formula (XII):(XII);and a compound of Formula (XIII):UIX-05225(XIII);thereby forming the compound of Formula (III);wherein:A is aryl or heteroaryl;B is a boron having sp3hybridization;n is an integer selected from 0, 1, 2, 3, or 4;X1is a halogen;R20is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl;R21is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R22is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R23is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;R24is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; andR25is, independently for each occurrence, selected from the group consisting of alkyl, cycloalkyl, alkoxy, acyl, aryl, heteroaryl, heterocyclyl, cyano, nitro, and sulfonyl.
36. The method of claim 35, wherein A is phenyl.
37. The method of claim 35 or 36, wherein R25is H.
38. The method of any one of claims 35-37, wherein X1is chloro or bromo.
39. The method of any one of claims 35-48, wherein each of R20, R21, R22, R23, and R24is methyl.
40. The method of claim 35, wherein the compound of Formula (XII) is:salt thereof.UIX-0522541. The method of claim 35, wherein the compound of Formula (XIII) is:
